Affymax, Inc.
News and overview for Affymax, Inc.
Affymax Prices Public Offering of Common Stock [Press Release]
Business Wire | 5 days 7 hours 32 minutes ago
Affymax, Inc. (Nasdaq:AFFY) today announced that it has priced an underwritten public offering of 4,109,589 shares of its common stock at a price of $18.25 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $69.6 million. Affymax has granted the underwriters a thirty-day option to purchase up to 616,438 additional shares of common stock to cover overallotments, if any. The offering is expected to close on or about Nove...
Affymax Reports Third Quarter 2009 Financial Results [Press Release]
Business Wire | 20 days 9 hours 3 minutes ago
Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008.
Affymax Announces Proposed Public Offering of Common Stock [Press Release]
Business Wire | 6 days 32 minutes ago
Affymax, Inc. (Nasdaq: AFFY), today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. Affymax expects to grant the underwriters a thirty-day option to purchase additional shares of common stock to cover overallotments, if any.
Affymax and Takeda Announce Hematide Publication in the New England Journal of Medicine [Press Release]
Business Wire | 19 days 23 hours 33 minutes ago
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from a Phase 2 clinical trial of Hematide™ showing that Hematide increased hemoglobin and reduced or eliminated the need for blood transfusion in most patients with erythropoietin-induced pure red cell aplasia (PRCA). The data were published in the 5th November 2009 issue of the New England Journal of Medicine.
Affymax Names Hollings C. Renton Chairman of the Board of Directors [Press Release]
Business Wire | 21 days 6 hours 3 minutes ago
Affymax, Inc. (Nasdaq:AFFY) today announced the appointment of Hollings C. Renton to the position of chairman of the company’s board of directors effective December 1, 2009. Mr. Renton replaces Nick Galakatos, who served as lead board member since the company’s initial public offering in 2006 and who will be resigning his position as a member of the board of directors at the end of 2009.
Affymax Announces Completion of Final Scheduled Data Monitoring Committee Review of Phase 3 Hematide Program [Press Release]
Business Wire | 14 days 8 hours 33 minutes ago
Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide™, has completed its final scheduled review and has informed the company that the cumulative safety data generated thus far from the EMERALD and PEARL Phase 3 trials support continuation of the studies. While no additional meetings are planned, the DMC, under its charter, can request additional information regarding the studies at any t...
Affymax to make multiple presentations highlighting Hematide preclinical and clinical data
News-Medical.Net | 33 days 8 hours 10 minutes ago
Affymax, Inc. (Nasdaq:AFFY) today announced multiple presentations at the American Society of Nephrology (ASN) Renal Week 2009 taking place October 27 through November 1 in San Diego.
Affymax appoints board member as new chairman
Forbes | 21 days 4 hours 36 minutes ago
PALO ALTO, Calif. -- Drug developer Affymax Inc. said Tuesday it has appointed board member Hollings Renton as chairman, effective Dec. 1.
Affymax to make multiple presentations on preclinical and clinical data of Hematide
News-Medical.Net | 32 days 16 hours 55 minutes ago
Affymax, Inc. (Nasdaq:AFFY) today announced multiple presentations at the American Society of Nephrology (ASN) Renal Week 2009 taking place October 27 through November 1 in San Diego.
Affymax 3Q loss narrows partnership payments
Forbes | 20 days 5 hours 50 minutes ago
PALO ALTO, Calif. -- Biotechnology company Affymax Inc. said Wednesday its third-quarter loss narrowed on a boost in payments from its partner Takeda Pharmaceutical on the anemia drug candidate Hematide.
Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That Hematide Increased Hemoglobin in Dialysis Patients [Press Release]
Business Wire | 25 days 3 hours 33 minutes ago
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients. This is the first reported data from an open-label, controlled comparative study of once-monthly Hematide compared to three times per week epoetin alfa...
Affymax: Hematide helped treat anemia in dialysis
Forbes | 25 days 31 minutes ago
NEW YORK -- Affymax Inc. said Friday its drug candidate Hematide was successful in a clinical study as a treatment for anemia in patients on dialysis.
Affymax's 3rd-quarter loss narrows on larger payment from anemia drug partnership -- South Florida Sun-Sentinel.com
Sun-Sentinel (Fort Lauderdale, Fla.) | 20 days 6 hours 13 minutes ago
PALO ALTO, Calif. (AP) — Biotechnology company Affymax Inc. said Wednesday its third-quarter loss narrowed on a boost in payments from its partner Takeda Pharmaceutical on the anemia drug candidate Hematide.
Affymax plans to offer 2.5M shares of stock
CNBC | 5 days 6 hours 56 minutes ago
NEW YORK - Biotechnology company Affymax Inc. said late Wednesday it plans to sell 2.5 million new shares of stock in a public offering.
Affymax plans to raise $69.6M in stock sale
American City Business Journals | 5 days 5 hours 58 minutes ago
Biopharmaceutical company Affymax Inc. said Thursday it plans to offer about 4 million shares of its common stock to raise $69.
Sign up for FDLI SmartBrief
Company Overview
| Company: | Affymax, Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.affymax.com |
Affymax is designing peptides to give red blood cells a pep talk. The biotechnology firm is researching and developing possible drugs based upon these biological process regulators. Its leading drug candidate, Hematide, is an erythropoietin (EPO) mimetic, designed to stimulate red blood cell production, like EPO itself. Hematide is being investigated as a possible treatment for anemia caused by chronic renal failure and chemotherapy. Affymax believes Hematide will be cheaper and longer lasting than the EPO stimulants currently used on dialysis patients.
Key Numbers
| Sales in U.S. Dollars (mil.) | 82.9 (2008) |
|---|---|
| One-year % Growth in Sales | 86.9 (2008) |
| Net Income in U.S. Dollars (mil.) | -86.5 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 147 (2008) |
| One-year % Growth in Number of Employees | -2.6 (2008) |
| Fiscal Year-End | December |